Eisai Co., Ltd.｜A human health care company

Lymphatic Filariasis Elimination Activities in Papua New Guinea

Eisai Donated Masks and Gloves for COVID-19 Countermeasures in Mass Drug Administration
Eisai's Statement of Commitment for Carbon Neutrality by 2040

Medium- to long-term goals to achieve carbon neutrality
Video Library

Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines
Lymphatic Filariasis Elimination Activities in Kenya

Support for MDA and Provision of Water Tanks
Making our medicines available to those who need them

10 Years of Progress toward Elimination of Lymphatic Filariasis

News Release
Latest News
Information

April 19, 2021

Eisai formulates the action plan “Diversity & Inclusion 2021”
December 10, 2020

Notice of Emergence of Employees Infected with the Novel Coronavirus at the Bogor Plant in Indonesia
December 3, 2020

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY
October 28, 2020

INTERNATIONAL NONPROPRIETARY NAME FOR ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY BAN2401 DECIDED AS LECANEMAB
August 4, 2020

Notice of Emergence of Employees Infected with the Novel Coronavirus at Eisai’s Vizag Plant in India

Eisai at a Glance

Eisai Group Worldwide

About Eisai

About Eisai TOP

Our pursuit of human health care (hhc)

Eisai's hhc Philosophy

Eisai's hhc Philosophy TOP

Investors

Sustainability

Making our medicines available to those who need them

28 countries 2.02 billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2021)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP